Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986022 | 0.83 | HSD11B1 (0.50) | HSD11B1HSD17B10L3MBTL1EPHX2DPP4 | |
| SCHEMBL18986023 | 0.83 | HSD11B1 (0.50) | HSD11B1HSD17B10L3MBTL1EPHX2DPP4 | |
| SCHEMBL2604736 | 0.82 | HSD11B1 (0.60) | HSD11B1HSD17B10L3MBTL1EPHX2NPC1 | |
| SCHEMBL5158011 | 0.81 | HSD11B1 (0.51) | HSD11B1HSD17B10L3MBTL1EPHX2SMN1; SMN2 | |
| SCHEMBL18985854 | 0.81 | HSD11B1 (0.48) | HSD11B1HSD17B10L3MBTL1EPHX2DPP4 | |
| SCHEMBL18985851 | 0.81 | HSD11B1 (0.48) | HSD11B1HSD17B10L3MBTL1EPHX2DPP4 | |
| SCHEMBL5157584 | 0.78 | HSD11B1 (0.67) | HSD11B1HSD17B10L3MBTL1EPHX2NPC1 | |
| SCHEMBL6504402 | 0.75 | HSD11B1 (0.65) | HSD11B1HSD17B10L3MBTL1EPHX2 | |
| SCHEMBL20574608 | 0.75 | ACE2 (0.50) | HSD11B1 | |
| SCHEMBL5175433 | 0.74 | HSD11B1 (0.61) | HSD11B1HSD17B10L3MBTL1EPHX2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745019-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005108359-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HSD11B1 2/4885HSD17B10 26/4885L3MBTL1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.